Systemic treatment of humans
Since the pipeline of the pharma industry is running low and mostly limited to derivatives of existing antibiotics, the need for a new leading antimicrobial technology is obvious.
Artilysin® molecules are very versatile. They can be used to combat almost every problem caused by bacterial infections. In cases where antibiotics fail, Artilysin®s can be a real alternative.
There is a lot of evidence of their efficacy for treating a variety of human diseases, including infections of the urinary tract, pneumonia, cystic fibrosis and systemic infections like sepsis.
In initial mouse studies, including a sepsis model, Artilysin®s were also shown to be highly effective.
Studies on biocompatibility according to DIN EN 10993-5 and DIN EN 10993-10 were conducted. Artilysin®s proofed to be neither cytotoxic nor irritating or sensitising.
Additional tests showed that Artilysin®s have no effect on the viability of primary cells in the therapeutic frame. Six different primary cell lines were tested.
Mouse sepsis model
Local bacterial infections often extend to a systemic disease called sepsis. Only a fast and efficient diagnosis and treatment of these infections can hinder serious organ failures and may decrease the high mortality rate. Millions of patients die every year from these systemic infections and the global spread of multi-drug or even pan-drug resistant bacterial strains often make a classic antibiotic therapy completely ineffective. In order to demonstrate that Artilysin®s targeted towards Gram-negative pathogens are able to combat these kind of infections, Lysando asked the University of Gifu to analyse the efficacy of an Artilysin® in its established mouse sepsis model. It was shown that the Artilysin® dramatically increased the survival rate of mice infected with Pseudomonas aeruginosa and therefore proofed the potential of these molecules as new weapons against multidrug resistant pathogens in vivo.